50% off all subscriptions! ... left. Order NowOrder Now

Weaker Stock
Today ARDX ranks #13064 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$0.89 (-3.47%)

Volume: 2M

Closed: Nov 26, 2021

Hollow Logo Score: -6.004

Ardelyx Stock Forecast

$0.89 (-3.47%)

Volume: 2M

Closed: Nov 26, 2021

Score Hollow Logo -6.004
Which way will ARDX go? Request
Key Stats
Beta 0.49
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 11 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.

Ardelyx stock downgraded to Strong Sell Candidate
(Updated on Nov 26, 2021)


Sell candidate since 2021-11-26

The Ardelyx stock price fell by -3.47% on the last day (Friday, 26th Nov 2021) from $0.92 to $0.89. During the day the stock fluctuated 5.75% from a day low at $0.87 to a day high of $0.92. The price has fallen in 7 of the last 10 days and is down by -23.06% for this period. Volume has increased on the last day by 312 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $1.51 million.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $0.83 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -26.99% during the next 3 months and, with a 90% probability hold a price between $0.61 and $0.83 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

There are few to no technical positive signals at the moment. The Ardelyx stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.95 and $1.12. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, November 04, 2021, and so far it has fallen -28.02%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.0500 between high and low, or 5.75%. For the last week, the stock has had a daily average volatility of 6.27%.

Ardelyx is oversold on RSI14 (11). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Ardelyx stock A Buy?

Ardelyx holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -6.004

Predicted Opening Price for Ardelyx of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$0.89 $0.89 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Oct 14, 2021 "LADENBURG THALM/SH SH" gave "" rating for ARDX. The price target was changed from $1.09 to 17.4%.

Volatility and Risk
Daily Average Volatility: 6.27 %
Overall Risk: Very High High Medium Low Very Low
Volatility
6.27 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $1.02
Price: $0.89
No Support Found

ARDX Insider Trading Show all Trades

INSIDER POWER

3.738

Last 100 transactions
Buy: 3 747 091 | Sell: 1 002 453 (Shares)
Date Action Amount Person Type
Nov 22, 2021 Sell 643 Rodriguez Susan Common Stock
Nov 22, 2021 Sell 184 Rosenbaum David P. Common Stock
Nov 22, 2021 Sell 643 Rosenbaum David P. Common Stock
Nov 22, 2021 Sell 537 Grammer Elizabeth A Common Stock
Nov 22, 2021 Sell 643 Blanks Robert Common Stock
Show all Insider Trades
INSIDER POWER

3.738

Last 100 transactions
Buy: 3 747 091 | Sell: 1 002 453 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.94 5.79 %
0.93 3.65 %
0.91 2.33 %
Current price: 0.89
Support 0.88 -1.95 %
0.86 -3.28 %
0.84 -5.42 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 1.09 22.13 %
1.05 17.65 %
1.02 14.29 %
Current price 0.89
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Ardelyx

Ardelyx Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic therapeutics for the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome, as well as in Phase IIb clinical trial for the treatment of hyperphosphatemia or elevated serum phosphorus levels in patients... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT